JNJ Company Profile and Key Details

Q: Who are the executives of JNJ?

Mr. Robert J. Decker Jr.Controller & Chief Accounting OfficerDr. Peter M. Fasolo Ph.D.Executive Vice President & Chief HR OfficerMs. Elizabeth ForminardExecutive Vice President & Gen. CounselMr. Alex GorskyExecutive ChairmanDr. Guy J. Lebeau M.D.Group Chairman of MD&D Bus. - EMEAMr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial OfficerMs. Ashley A. McEvoyExecutive Vice President & Worldwide Chairman of MedTechMr. Thibaut MongonChief Executive Officer & DirectorMs. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of PharmaceuticalsDr. John C. Reed M.D., Ph.D.Executive Vice President of Pharmaceuticals R&DMr. Joseph J. Wolk CPAExecutive Vice President & Chief Financial OfficerMr. Dirk BrinckmanChief Compliance OfficerMr. Joaquin DuatoChief Executive Officer & DirectorMr. James SwansonExecutive Vice President & Chief Information OfficerMs. Jessica MooreVice President of Investor Relations

NYSE : JNJ

Johnson & Johnson

$239.99

2.2+0.93%

At Close 4:00 PM

73.93

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Johnson & Johnson (JNJ) stock surged +0.93%, trading at $239.99 on NYSE, up from the previous close of $237.79. The stock opened at $238.96, fluctuating between $238.00 and $240.94 in the recent session.

Stock Snapshot

237.79

Prev. Close

578.21B

Market Cap

238

Day Low

21.76

P/E Ratio

11.03

EPS (TTM)

6.52

Cash Flow per Share

238.96

Open

2.41B

Number of Shares

240.935

Day High

99.84%

Free Float in %

28.3

Book Value

8.27M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	238.96	240.94	237.98	239.99	8.26M
Feb 05, 2026	235.00	239.58	234.99	237.79	10.22M
Feb 04, 2026	235.00	235.83	232.94	234.47	8.63M
Feb 03, 2026	231.50	235.20	230.48	233.10	9.32M
Feb 02, 2026	228.32	231.19	227.25	230.75	8.18M
Jan 30, 2026	228.26	228.50	225.33	227.25	11.03M
Jan 29, 2026	228.81	230.00	227.08	227.29	9.24M
Jan 28, 2026	226.40	228.57	226.08	227.72	8.96M
Jan 27, 2026	222.00	225.50	220.70	224.44	8.15M
Jan 26, 2026	220.21	222.03	220.00	221.49	6.35M
Jan 23, 2026	219.80	221.21	217.84	220.14	6.79M
Jan 22, 2026	218.77	222.17	218.10	218.49	12.24M
Jan 21, 2026	211.00	218.68	210.50	218.01	14.74M
Jan 20, 2026	217.09	218.73	214.50	218.21	13.81M
Jan 16, 2026	219.04	220.11	218.14	218.66	9.7M
Jan 15, 2026	218.23	219.75	215.91	219.57	7.75M
Jan 14, 2026	214.73	218.86	214.15	218.55	11.78M
Jan 13, 2026	209.91	214.39	208.86	213.65	10.82M
Jan 12, 2026	205.55	209.90	203.85	209.72	11.78M
Jan 09, 2026	205.91	206.70	204.01	204.39	6.15M

Contact Details

New Brunswick, NJ 08933

United States

https://www.jnj.com 732 524 0400

About Company

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Stock Peers

LLY

37.34+3.66%

Eli Lilly and Company$1,058.18 ABBV

4.41+2.01%

AbbVie Inc.$223.43 NVS

2.47+1.60%

Novartis AG$156.42 MRK

2.18+1.82%

Merck & Co., Inc.$121.93 BMY

2.47+4.15%

Bristol-Myers Squibb Company$61.99 GSK

1.06+1.79%

GSK plc$60.23 NVO

4.3+9.92%

Novo Nordisk A/S$47.64 PFE

0.73+2.76%

Pfizer Inc.$27.22 OGN

0.11+1.36%

Organon & Co.$8.21 SRXH

-0.0029-2.25%

SRx Health Solutions Inc.$0.13

Company Overview

Johnson & Johnson (NYSE:JNJ) closed at $239.99 USD, gaining $2.20 (0.93%) from the previous close of $237.79. The stock is currently trading near its 52-week high $141.50 and $240.94. With a market capitalization of about $578.21 billion, Johnson & Johnson is classified as a mega-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 9.05 million shares, in line with its 52-week average. Headquartered in New Brunswick, NJ, Johnson & Johnson operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Joaquin Duato, the company employs approximately 138,100 people and listed since January 02, 1943. Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.

Technical Performance

JNJ has shown sold momentum, gaining 4.05% over the past week and 12.93% over the past quarter, though year-to-date performance is up 5.44%. Short-term trend indicators are bearishly aligned (SMA20 7.53%, SMA50 12.53%, SMA200 32.09%). The stock’s 14-day RSI is 86.55 (overbought), while the ATR of 3.83 points to moderate volatility. The stock remains currently trading near 52-week highs, trading 0.17% below its high and over 69.6% above its low. Average 10-day trading volume of 9.11 million shares is in line with the 3-month average of 8.62 million, indicating normal recent market interest.

Valuation Metrics

Johnson & Johnson trades at a P/E ratio of 21.79, slightly below the S&P 500 average, with a price-to-sales ratio of 6.15 and a price-to-book ratio of 7.37 trading at moderately above to book value. The P/FCF stands at 30.39, also above market averages.

Dividend & Fair Value

Johnson & Johnson last paid a dividend of 5.14 per share, this equals a trailing yield of roughly 3.09%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $254.71. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Johnson & Johnson generated EPS of $11.05 over the past year. Five-year average earnings growth is 14.9%. Wall Street analysts project EPS growth of 8.29% annually over the next five years. The latest quarter delivered EPS of $2.80. The next quarter is forecast at $2.69. Next year's EPS is expected at $7.19. Analyst sentiment is neutral. Analyst rating data shows there are 12 Strong Buy ratings, 14 Buy ratings, 25 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $265.00 to $159.00. The high target offers 10.42% upside. The low target suggests -33.75% downside. The mean target is $204.47. This offers -14.8% upside. Johnson & Johnson earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 14, 2025, missed forecasts by 1.45%. The prior quarter beat by 3.36%. Over the last six quarters, Apple has recorded several small beats. These include 4.06% in July 17, 2024.

Shareholding & Insider Activity

Johnson & Johnson has 2.41 billion shares outstanding. The public float is 2.40 billion shares, elevated short interest at 0.71% of float. This equals 17.14 million shares. The short ratio is 2.0 days. Institutional investors hold 74.41% of the float. Insiders own 0.06%. Taubert Jennifer L holds 178.01 thousand shares, Fasolo Peter has 102.70 thousand shares and Hait William has 87.75 thousand shares. Over the past six months, insider transactions show net selling. They sold 269.62 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Johnson & Johnson generated $85.15B in revenue, or $33.26 per share. Gross margin was 68.60%, operating margin 25.66%, and net profit margin 41.28%. Returns are exceptional, with ROA at 20.98% and ROE at 51.11%.
On valuation metrics, Johnson & Johnson trades at a P/E of 21.79, P/S of 6.15 and P/B of 7.37. The current ratio is 1.07 and quick ratio is 0.80. Operationally, the company’s inventory turnover is 1.81 and cash conversion cycle is 132.61 days. Debt-to-equity is 0.58, supported by a cash flow-to-debt ratio of 0.53.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Johnson & Johnson posted revenue of $85.15B, down slightly from $94.94B in the prior quarter. Gross profit was $58.41B (margin 68.60%). Operating income was $21.85B (margin 25.7%). Net income was$35.15B (EPS $14.60).
The company ended the quarter with $22.93B in cash and short-term investments, a total debt of $30.43B, and net debt of $8.57B. Total assets were $167.56B, with equity of $68.77B. Financials further reflected stability, with operating cash flow of $22.79B, free cash flow of $18.25B, and capital expenditures of - $4.54B.

Price Forecast & Outlook

Our AI price prediction model suggests that Johnson & Johnson stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.17%, with price expected at $252.40 by February 19, 2026, within a range of $245.33 to $259.67 3-Month Outlook: Projected rise of 42.17%, reaching $341.20 by May 06, 2026, with a range of $332.20 to $352.61. 1-Year Outlook: Projected gain of 1.15%, with price at $242.76 by February 05, 2027, within a range of $236.38 to $248.88.

Key Takeaways

Johnson & Johnson (NYSE:JNJ) shares are flat 5.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Johnson & Johnson trading at a premium to the broader market with a P/E of 21.79. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $188.65, suggesting -21.39% downside. Our AI forecast model points to short-term strength (5.17% over two weeks), a medium-term rise (42.17% over three months), and a longer-term gain (1.15% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Johnson & Johnson (JNJ) stock price?

Johnson & Johnson (NYSE: JNJ) stock price is $239.99 in the last trading session. During the trading session, JNJ stock reached the peak price of $240.94 while $238.00 was the lowest point it dropped to. The percentage change in JNJ stock occurred in the recent session was 0.93% while the dollar amount for the price change in JNJ stock was $2.20.

JNJ's industry and sector of operation?

The NYSE listed JNJ is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Johnson & Johnson designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of JNJ?

Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer
Dr. Peter M. Fasolo Ph.D.
Executive Vice President & Chief HR Officer
Ms. Elizabeth Forminard
Executive Vice President & Gen. Counsel
Mr. Alex Gorsky
Executive Chairman
Dr. Guy J. Lebeau M.D.
Group Chairman of MD&D Bus. - EMEA
Mr. Joseph J. Wolk C.P.A.
Executive Vice President & Chief Financial Officer
Ms. Ashley A. McEvoy
Executive Vice President & Worldwide Chairman of MedTech
Mr. Thibaut Mongon
Chief Executive Officer & Director
Ms. Jennifer L. Taubert
Executive Vice President & Worldwide Chairman of Pharmaceuticals
Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Pharmaceuticals R&D
Mr. Joseph J. Wolk CPA
Executive Vice President & Chief Financial Officer
Mr. Dirk Brinckman
Chief Compliance Officer
Mr. Joaquin Duato
Chief Executive Officer & Director
Mr. James Swanson
Executive Vice President & Chief Information Officer
Ms. Jessica Moore
Vice President of Investor Relations

How JNJ did perform over past 52-week?

JNJ's closing price is 69.6% higher than its 52-week low of $141.50 where as its distance from 52-week high of $240.94 is -0.39%.

How many employees does JNJ have?

Number of JNJ employees currently stands at 138,100.

Link for JNJ official website?

Official Website of JNJ is: https://www.jnj.com

How do I contact JNJ?

JNJ could be contacted at phone 732 524 0400 and can also be accessed through its website. JNJ operates from One Johnson & Johnson Plaza, New Brunswick, NJ 08933, United States.

How many shares of JNJ are traded daily?

JNJ stock volume for the day was 8.27M shares. The average number of JNJ shares traded daily for last 3 months was 9.05M.

What is the market cap of JNJ currently?

The market value of JNJ currently stands at $578.21B with its latest stock price at $239.99 and 2.41B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	138100
Beta	0.33
Sales or Revenue	$85.15B
5Y Sales Change%	0.097%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

JNJ Company Profile and Key Details

Johnson & Johnson

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook